Literature DB >> 1504087

Localization and characterization of hemoglobin-degrading aspartic proteinases from the malarial parasite Plasmodium falciparum.

D L vander Jagt1, L A Hunsaker, N M Campos, J V Scaletti.   

Abstract

Three hemoglobin-degrading proteinases were partially purified from food vacuoles isolated from trophozoite-stage forms of the malarial parasite Plasmodium falciparum. Two of the proteinases (M1 and M2) were solubilized by repeated sonication. The remaining proteinase (M3) was solubilized by treatment of the particulate fraction with taurocholic acid, suggesting that proteinase M3 is a membrane-bound proteinase whereas proteinases M1 and M2 are weakly associated with parasite membrane. The location of these proteinases suggests that they may participate in the digestion of host cytosolic protein. After partial purification, but not before, proteinases M1, M2 and M3 are highly sensitive to pepstatin, supporting their designation as aspartic proteinases. These aspartic proteinases show broad specificity for protein substrates. Native hemoglobin, acid denatured hemoglobin and oxidatively damaged hemoglobin are comparable substrates. Hemoglobin within the food vacuole was shown to be primarily native hemoglobin. Chemical modification studies indicate that these three aspartic proteinases have similar properties. The peptide maps from degradation of hemoglobin, however, suggest that aspartic proteinases M1, M2 and M3 are distinct proteinases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1504087     DOI: 10.1016/0167-4838(92)90401-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  12 in total

1.  Transcriptomic and proteomic profile of Aspergillus fumigatus on exposure to artemisinin.

Authors:  Poonam Gautam; Santosh Kumar Upadhyay; Wazid Hassan; Taruna Madan; Ravi Sirdeshmukh; Curam Sreenivasacharlu Sundaram; Wasudev Namdeo Gade; Seemi Farhat Basir; Yogendra Singh; Puranam Usha Sarma
Journal:  Mycopathologia       Date:  2011-07-14       Impact factor: 2.574

2.  Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors.

Authors:  P J Rosenthal; J E Olson; G K Lee; J T Palmer; J L Klaus; D Rasnick
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

Review 3.  Malaria parasite plasmepsins: More than just plain old degradative pepsins.

Authors:  Armiyaw S Nasamu; Alexander J Polino; Eva S Istvan; Daniel E Goldberg
Journal:  J Biol Chem       Date:  2020-05-04       Impact factor: 5.157

Review 4.  The role of antioxidants treatment on the pathogenesis of malarial infections: a review.

Authors:  Murtala Bindawa Isah; Mohammed Auwal Ibrahim
Journal:  Parasitol Res       Date:  2014-02-13       Impact factor: 2.289

Review 5.  Oxidative stress in malaria; implications for prevention and therapy.

Authors:  N S Postma; E C Mommers; W M Eling; J Zuidema
Journal:  Pharm World Sci       Date:  1996-08

6.  Order and specificity of the Plasmodium falciparum hemoglobin degradation pathway.

Authors:  I Y Gluzman; S E Francis; A Oksman; C E Smith; K L Duffin; D E Goldberg
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

7.  In vitro activity of riboflavin against the human malaria parasite Plasmodium falciparum.

Authors:  T Akompong; N Ghori; K Haldar
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

8.  Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling.

Authors:  C S Gavigan; S G Machado; J P Dalton; A Bell
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 9.  Malarial hemozoin: from target to tool.

Authors:  Lorena M Coronado; Christopher T Nadovich; Carmenza Spadafora
Journal:  Biochim Biophys Acta       Date:  2014-02-17

10.  Functional expression of falcipain, a Plasmodium falciparum cysteine proteinase, supports its role as a malarial hemoglobinase.

Authors:  F Salas; J Fichmann; G K Lee; M D Scott; P J Rosenthal
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.